Stem cell modeling of mitochondrial parkinsonism reveals key functions of OPA1

被引:21
作者
Jonikas, Mindaugas [1 ]
Madill, Martin [1 ]
Mathy, Alexandre [1 ]
Zekoll, Theresa [1 ]
Zois, Christos E. [2 ]
Wigfield, Simon [2 ]
Kurzawa-Akanbi, Marzena [3 ]
Browne, Cathy [4 ]
Sims, David [5 ]
Chinnery, Patrick F. [6 ,7 ]
Cowley, Sally A. [4 ]
Tofaris, George K. [1 ]
机构
[1] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England
[2] Univ Oxford, Weatherall Inst Mol Med, Dept Oncol, Oxford, England
[3] Newcastle Univ, Mitochondrial Res Grp, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Oxford, Sir William Dunn Sch Pathol, James Martin Stem Cell Facil, Oxford, England
[5] Univ Oxford, MRC Weatherall Inst Mol Med, MRC WIMM Ctr Computat Biol, MRC Computat Genom Anal & Training Programme, Oxford, England
[6] Univ Cambridge, Dept Clin Neurosci, Cambridge, England
[7] MRC Mitochondrial Biol Unit, Cambridge Biomed Campus, Cambridge, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
DOMINANT OPTIC ATROPHY; OXIDATIVE-PHOSPHORYLATION; MUTATIONS; FUSION; NEURONS; OMA1; PLURIPOTENCY; MAINTENANCE; APOPTOSIS; DEMENTIA;
D O I
10.1002/ana.25221
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveDefective mitochondrial function attributed to optic atrophy 1 (OPA1) mutations causes primarily optic atrophy and, less commonly, neurodegenerative syndromes. The pathomechanism by which OPA1 mutations trigger diffuse loss of neurons in some, but not all, patients is unknown. Here, we used a tractable induced pluripotent stem cell (iPSC)-based model to capture the biology of OPA1 haploinsufficiency in cases presenting with classic eye disease versus syndromic parkinsonism. MethodsiPSCs were generated from 2 patients with OPA1 haploinsufficiency and 2 controls and differentiated into dopaminergic neurons. Metabolic profile was determined by extracellular flux analysis, respiratory complex levels using immunoblotting, and complex I activity by a colorimetric assay. Mitochondria were examined by transmission electron microscopy. Mitochondrial DNA copy number and deletions were assayed using long-range PCR. Mitochondrial membrane potential was measured by tetramethylrhodamine methyl ester uptake, and mitochondrial fragmentation was assessed by confocal microscopy. Exome sequencing was used to screen for pathogenic variants. ResultsOPA1 haploinsufficient iPSCs differentiated into dopaminergic neurons and exhibited marked reduction in OPA1 protein levels. Loss of OPA1 caused a late defect in oxidative phosphorylation, reduced complex I levels, and activity without a significant change in the ultrastructure of mitochondria. Loss of neurons in culture recapitulated dopaminergic degeneration in syndromic disease and correlated with mitochondrial fragmentation. InterpretationOPA1 levels maintain oxidative phosphorylation in iPSC-derived neurons, at least in part, by regulating the stability of complex I. Severity of OPA1 disease associates primarily with the extent of OPA1-mediated fusion, suggesting that activation of this mechanism or identification of its genetic modifiers may have therapeutic or prognostic value. Ann Neurol 2018;83:915-925
引用
收藏
页码:915 / 925
页数:11
相关论文
共 50 条
  • [21] The short variant of the mitochondrial dynamin OPA1 maintains mitochondrial energetics and cristae structure
    Lee, Hakjoo
    Smith, Sylvia B.
    Yoon, Yisang
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (17) : 7115 - 7130
  • [22] Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1
    Kieper, Nicole
    Holmstroem, Kira M.
    Ciceri, Dalila
    Fiesel, Fabienne C.
    Wolburg, Hartwig
    Ziviani, Elena
    Whitworth, Alexander J.
    Martins, L. Miguel
    Kahle, Philipp J.
    Krueger, Rejko
    EXPERIMENTAL CELL RESEARCH, 2010, 316 (07) : 1213 - 1224
  • [23] Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth
    Zamberlan, Margherita
    Boeckx, Amandine
    Muller, Florian
    Vinelli, Federica
    Ek, Olivier
    Vianello, Caterina
    Coart, Emeline
    Shibata, Keitaro
    Christian, Aurelie
    Grespi, Francesca
    Giacomello, Marta
    Struman, Ingrid
    Scorrano, Luca
    Herkenne, Stephanie
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [24] OPA1 and mitochondrial solute carriers in bioenergetic metabolism
    Germain, Marc
    MOLECULAR & CELLULAR ONCOLOGY, 2015, 2 (02):
  • [25] Derivation and Characterization of Isogenic OPA1 Mutant and Control Human Pluripotent Stem Cell Lines
    Pohl, Katherine A.
    Zhang, Xiangmei
    Ji, Johnny Jeonghyun
    Stiles, Linsey
    Sadun, Alfredo A.
    Yang, Xian-Jie
    CELLS, 2025, 14 (02)
  • [26] Mitochondrial Function: OMA1 and OPA1, the Grandmasters of Mitochondrial Health
    McBride, Heidi
    Soubannier, Vincent
    CURRENT BIOLOGY, 2010, 20 (06) : R274 - R276
  • [27] Mitochondrial dysfunction in an Opa1Q285STOP mouse model of dominant optic atrophy results from Opa1 haploinsufficiency
    Kushnareva, Y.
    Seong, Y.
    Andreyev, A. Y.
    Kuwana, T.
    Kiosses, W. B.
    Votruba, M.
    Newmeyer, D. D.
    CELL DEATH & DISEASE, 2016, 7 : e2309 - e2309
  • [28] OPA1 functions in mitochondria and dysfunctions in optic nerve
    Lenaers, Guy
    Reynier, Pascal
    ElAchouri, Ghizlane
    Soukkarieh, Chadi
    Olichon, Aurelien
    Belenguer, Pascale
    Baricault, Laurent
    Ducommun, Bernard
    Hamel, Christian
    Delettre, Cecile
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (10) : 1866 - 1874
  • [29] Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamics
    Alavi, Marcel V.
    Fuhrmann, Nico
    MOLECULAR NEURODEGENERATION, 2013, 8
  • [30] Chchd2 regulates mitochondrial morphology by modulating the levels of Opa1
    Liu, Wei
    Duan, Xiuying
    Xu, Lingna
    Shang, Weina
    Zhao, Jiayao
    Wang, Liquan
    Li, Jian-Chiuan
    Chen, Chun-Hong
    Liu, Jun-Ping
    Tong, Chao
    CELL DEATH AND DIFFERENTIATION, 2020, 27 (06) : 2014 - 2029